



**Universiteit
Leiden**
The Netherlands

Population pharmacokinetics of antibiotics to prevent group B streptococcal disease: from mother to neonate

Muller, A.E.

Citation

Muller, A. E. (2009, February 11). *Population pharmacokinetics of antibiotics to prevent group B streptococcal disease: from mother to neonate*. Department of Obstetrics and Gynaecology of the Medical Center Haaglanden, The Hague|Faculty of Science, Leiden University. Retrieved from <https://hdl.handle.net/1887/13469>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13469>

Note: To cite this publication please use the final published version (if applicable).

Population pharmacokinetics of
antibiotics to prevent group B
streptococcal disease:
from mother to neonate

The work presented in this thesis was conducted at the department of obstetrics and gynaecology of the Medical Center Haaglanden, the Hague.

The research presented in this thesis was financially supported by Stichting Nuts Ohra (project number SNO-T-06-31), Medical Center Haaglanden and Leiden/Amsterdam Center for Drug Research.

The printing of this thesis was financially supported by:

Medical Center Haaglanden

Astra Zeneca B.V.

Pfizer B.V.

Bayer B.V.

Leiden/Amsterdam Center for Drug Research

Nederlandse Vereniging voor Obstetrie en Gynaecologie

Printed by: Optima Grafische Communicatie, Rotterdam

Cover: Beach Kijkduin, photographed and adapted by the author

ISBN: 978-90-8559-491-8

© A.E.Muller, The Netherlands, 2009. All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by other means, without prior written permission by the author.

Population pharmacokinetics of
antibiotics to prevent group B
streptococcal disease:
from mother to neonate

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof.mr. P.F.van der Heijden,
volgens het besluit van het College voor Promoties
te verdedigen op woensdag 11 februari 2009
klokke 13:45 uur

door
Anouk Edwina Muller
geboren te Den Haag
in 1977

Promotiecommissie

Promotores: Prof. dr. M. Danhof
Prof. dr. E.A.P. Steegers

Co-promotores: Dr. P.J. Dörr
Dr. J.W. Mouton

Referent: Prof. dr. H.J. Guchelaar

Leden: Prof. dr. F.M. Helmerhorst
Prof. dr. W. Jiskoot
Prof. dr. H.A. Verbrugh
Prof. dr. A.P. IJzerman

Everything is impossible until it has been done.

Dr. Tore Godal, 2005

Contents

Abbreviations	8
Part I General introduction	
Chapter 1	11
Population pharmacokinetics of antibiotics to prevent group B streptococcal disease: Scope and outline of the investigations.	
Chapter 2	19
Antibiotics in the prevention of neonatal group B streptococcal infections: the evidence.	
Chapter 3	45
Morbidity related to maternal group B streptococcal infections.	
Part II Antibiotic treatment during pregnancy and delivery: amoxicillin as prototype.	
Chapter 4	69
Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes.	
Chapter 5	85
The influence of labor on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.	
Chapter 6	103
Clavulanic acid does not influence amoxicillin pharmacokinetics in pregnant women during labor.	
Chapter 7	115
Pharmacokinetics of amoxicillin in maternal, umbilical cord and neonatal serum.	

Chapter 8	133
Evaluation of dosing regimen on amoxicillin exposure in pregnant women with preterm premature rupture of the membranes using Monte Carlo Simulation.	
Chapter 9	145
Aberrant amoxicillin pharmacokinetics in a pregnant patient with severe vomiting: a case-report.	
Part III Other antibiotics in the prevention and treatment of group B streptococcal infections.	
Chapter 10	157
The pharmacokinetics of clindamycin in pregnant women in the peripartum period.	
Chapter 11	173
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks.	
Part IV General conclusions and perspectives.	
Chapter 12	191
Population pharmacokinetics of antibiotics to prevent group B streptococcal disease: Summary, conclusions and perspectives.	
Summary in Dutch (Samenvatting in het Nederlands)	207
Authors and their affiliations	221
Nawoord	223
Curriculum Vitae	225
Publications	226
Color figures	227

Abbreviations

AF	Amniotic fluid
AUC	Area under the curve
BW	Body weight
CDC	Centers for Disease Control and Prevention
CFU	Colony forming units
CG	Cockcroft-Gault
CI	Confidence interval
CL	Clearance
CSF	Cerebrospinal fluid
CV	Coefficient of variation
EOD	Early-onset disease
Eta	Inter-individual variation NONMEM
EUCAST	European Committee on Antimicrobial Susceptibility Testing
F	Female
f	Unbound fraction of drug
$f_{T>MIC}$	The time the fraction not bound to proteins is above the MIC
GA	Gestational age
GBS	Group B streptococcus
GFR	Glomerular filtration rate
HPLC	High-pressure liquid chromatography
IAI	Intra-amniotic infection
IIV	Inter-individual variability
IPA	Intrapartum prophylaxis with antibiotics
LOD	Late-onset disease
M	Male
MCS	Monte Carlo Simulation
MDRD	Modification of Diet in Renal Disease
MIC	Minimum inhibitory concentration
NONMEM	Non-Linear Mixed Effects Modeling
OFV	Objective function value
PD	Pharmacodynamics
PK	Pharmacokinetics
PPROM	Premature preterm rupture of the membranes
PROM	Preterm rupture of the membranes
PTA	Probability of target attainment
Q	Intercompartmental clearance
SD	Standard deviation
SE	Standard error
$t_{1/2}$	Half-life
theta	Parameter in NONMEM
UTI	Urinary tract infection
V	Volume of distribution
V_{ss}	Volume of distribution at steady state